KR20210126045A - 전신 중증 근무력증을 치료하기 위한 항-c5 항체의 투여량 및 투여 - Google Patents

전신 중증 근무력증을 치료하기 위한 항-c5 항체의 투여량 및 투여 Download PDF

Info

Publication number
KR20210126045A
KR20210126045A KR1020217028172A KR20217028172A KR20210126045A KR 20210126045 A KR20210126045 A KR 20210126045A KR 1020217028172 A KR1020217028172 A KR 1020217028172A KR 20217028172 A KR20217028172 A KR 20217028172A KR 20210126045 A KR20210126045 A KR 20210126045A
Authority
KR
South Korea
Prior art keywords
antibody
patient
treatment
ser
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217028172A
Other languages
English (en)
Korean (ko)
Inventor
겐지 후지타
니시 람팔
웨이-지안 판
카우식 파트라
Original Assignee
알렉시온 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렉시온 파마슈티칼스, 인코포레이티드 filed Critical 알렉시온 파마슈티칼스, 인코포레이티드
Priority to KR1020267008814A priority Critical patent/KR20260046520A/ko
Publication of KR20210126045A publication Critical patent/KR20210126045A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217028172A 2019-02-14 2020-02-13 전신 중증 근무력증을 치료하기 위한 항-c5 항체의 투여량 및 투여 Ceased KR20210126045A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267008814A KR20260046520A (ko) 2019-02-14 2020-02-13 전신 중증 근무력증을 치료하기 위한 항-c5 항체의 투여량 및 투여

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962805350P 2019-02-14 2019-02-14
US62/805,350 2019-02-14
US201962814935P 2019-03-07 2019-03-07
US62/814,935 2019-03-07
PCT/US2020/018113 WO2020168079A1 (en) 2019-02-14 2020-02-13 Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267008814A Division KR20260046520A (ko) 2019-02-14 2020-02-13 전신 중증 근무력증을 치료하기 위한 항-c5 항체의 투여량 및 투여

Publications (1)

Publication Number Publication Date
KR20210126045A true KR20210126045A (ko) 2021-10-19

Family

ID=69954108

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217028172A Ceased KR20210126045A (ko) 2019-02-14 2020-02-13 전신 중증 근무력증을 치료하기 위한 항-c5 항체의 투여량 및 투여
KR1020267008814A Pending KR20260046520A (ko) 2019-02-14 2020-02-13 전신 중증 근무력증을 치료하기 위한 항-c5 항체의 투여량 및 투여

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020267008814A Pending KR20260046520A (ko) 2019-02-14 2020-02-13 전신 중증 근무력증을 치료하기 위한 항-c5 항체의 투여량 및 투여

Country Status (9)

Country Link
US (2) US20200331993A1 (enExample)
EP (1) EP3924380A1 (enExample)
JP (2) JP2022520107A (enExample)
KR (2) KR20210126045A (enExample)
CN (2) CN113614106A (enExample)
AU (1) AU2020223298A1 (enExample)
CA (1) CA3130300A1 (enExample)
MX (1) MX2021009789A (enExample)
WO (1) WO2020168079A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017269839A1 (en) 2016-05-27 2018-11-22 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
US12620484B2 (en) 2020-08-24 2026-05-05 Nvidia Corporation Machine-learning techniques for oxygen therapy prediction using medical imaging data and clinical metadata
EP4378479A3 (en) * 2021-01-22 2024-09-25 Alexion Pharmaceuticals, Inc. Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
US20250154232A1 (en) * 2021-07-14 2025-05-15 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
NZ711451A (en) * 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
SG10201710322VA (en) 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
AU2017269839A1 (en) * 2016-05-27 2018-11-22 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
WO2017218515A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
BR112020001703B1 (pt) * 2017-07-27 2024-01-02 Alexion Pharmaceuticals, Inc Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
EP3700928A1 (en) * 2017-10-26 2020-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)

Also Published As

Publication number Publication date
KR20260046520A (ko) 2026-04-07
JP2025092553A (ja) 2025-06-19
CN113614106A (zh) 2021-11-05
WO2020168079A1 (en) 2020-08-20
EP3924380A1 (en) 2021-12-22
MX2021009789A (es) 2021-11-17
CA3130300A1 (en) 2020-08-20
CN119326881A (zh) 2025-01-21
AU2020223298A1 (en) 2021-09-02
US20250243264A1 (en) 2025-07-31
JP2022520107A (ja) 2022-03-28
US20200331993A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
US20250243264A1 (en) Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis
JP2022126773A (ja) 難治性全身型重症筋無力症の処置のための方法
JP2022512632A (ja) 発作性夜間ヘモグロビン尿症（ｐｎｈ）の処置のための抗ｃ５抗体の皮下投薬及び投与
JP2023533682A (ja) 補体関連病態の処置用抗ｃ５抗体の皮下（ｓｃ）投与
JP2025084932A (ja) 視神経脊髄炎スペクトラム障害の治療のための抗ｃ５抗体
US20260022164A1 (en) Compositions and methods for the treatment of neuromyelitis optica spectrum disorder
US20250154232A1 (en) Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis
US20250066467A1 (en) Methods for the treatment of myasthenia gravis
JP2026515940A (ja) 補体障害の治療のための抗ｃ５抗体の小児投与量及び投与
EA046524B1 (ru) Доза и введение антител к c5 для лечения генерализованной миастении гравис
KR20250030978A (ko) 중증 근무력증의 치료를 위한 융합 폴리펩티드의 투여량 및 투여
WO2021263056A1 (en) Dosage and administration of anti-c5 antibodies for treatment of amyotrophic lateral sclerosis
EA050729B1 (ru) Антитело к с5 для лечения нейромиелита зрительного нерва со спектральным расстройством
WO2020106724A1 (en) Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
WO2025217677A1 (en) Methods for treating neutrophilic skin conditions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

B17 Application discontinued following pre-grant review

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B17-REX-PX0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104